Next-generation agents for fluorescence-guided glioblastoma surgery.

Autor: Chirizzi C; Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta' Politecnico di Milano Milano Italy., Pellegatta S; Unit of Immunotherapy of Brain Tumors Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy.; Unit of Neuroncology Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy., Gori A; National Research Council of Italy, Istituto di Scienze e Tecnologie Chimiche (SCITEC-CNR) Milan Italy., Falco J; Neurosurgical Unit 2, Department of Neurosurgery Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy., Rubiu E; Neurosurgical Unit 2, Department of Neurosurgery Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy., Acerbi F; Neurosurgical Unit 2, Department of Neurosurgery Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy.; Experimental Microsurgical Laboratory, Department of Neurosurgery Fondazione IRCCS Istituto Neurologico Carlo Besta Milano Italy., Bombelli FB; Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta' Politecnico di Milano Milano Italy.
Jazyk: angličtina
Zdroj: Bioengineering & translational medicine [Bioeng Transl Med] 2023 Oct 11; Vol. 9 (3), pp. e10608. Date of Electronic Publication: 2023 Oct 11 (Print Publication: 2024).
DOI: 10.1002/btm2.10608
Abstrakt: Glioblastoma is a fast-growing and aggressive form of brain cancer. Even with maximal treatment, patients show a low median survival and are often subjected to a high recurrence incidence. The currently available treatments require multimodal management, including maximal safe surgical resection, followed by radiation and chemotherapy. Because of the infiltrative glioblastoma nature, intraoperative differentiation of cancer tissue from normal brain parenchyma is very challenging, and this accounts for the low rate of complete tumor resection. For these reasons, clinicians have increasingly used various intraoperative adjuncts to improve surgical results, such as fluorescent agents. However, most of the existing fluorophores show several limitations such as poor selectivity, photostability, photosensitization and high costs. This could limit their application to successfully improve glioblastoma resection. In the present perspective, we highlight the possibility to develop next-generation fluorescent tools able to more selectively label cancer cells during surgical resection.
Competing Interests: Dr. Francesco Acerbi received honoraria from Carl Zeiss Meditec for lectures in International Meetings. Other authors declare no conflict of interest.
(© 2023 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje